LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging

• Published in: Biomaterials Vol. 71; pp. 84 - 99
• Main Authors: Roy, Kislay, Kanwar, Rupinder K., Kanwar, Jagat R.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.12.2015
• Subjects: AC133 Antigen; Animals; Antigens, CD - metabolism; Antigens, Neoplasm - metabolism; Aptamers, Nucleotide - chemistry; Bovine lactoferrin; Cadherins - metabolism; Cattle; Cell Adhesion Molecules - metabolism; Colon cancer stem cells; Colonic Neoplasms - diagnosis; Colonic Neoplasms - metabolism; Epithelial Cell Adhesion Molecule; Fe3O4; Ferric Compounds - chemistry; Gene Expression Profiling; Glycoproteins - metabolism; Heterografts; Imaging; Kinases; Lactoferrin - chemistry; Locked nucleic acid (LNA); Magnetic Resonance Imaging; Markers; Mice; Mice, Nude; Nanostructure; Nanostructures; Nanotheranostic; Oligonucleotides - chemistry; Peptides - metabolism; Proteins; Spectroscopy, Near-Infrared; Stem cells; Survivin; Tomography, X-Ray Computed; Tumors; Fe3O4; Locked nucleic acid (LNA); Bovine lactoferrin; Survivin; Colon cancer stem cells; Nanotheranostic; FeO
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2015.07.055

This is the first ever attempt to combine anti-cancer therapeutic effects of emerging anticancer biodrug bovine lactoferrin (bLf), and multimodal imaging efficacy of Fe3O4 nanoparticles (NPs) together, as a saturated Fe3O4-bLf. For cancer stem cell specific uptake of nanocapsules/nanocarriers (NCs), Fe3O4-bLf was encapsulated in alginate enclosed chitosan coated calcium phosphate (AEC-CP) NCs targeted (Tar) with locked nucleic acid (LNA) modified aptamers against epithelial cell adhesion molecule (EpCAM) and nucleolin markers. The nanoformulation was fed orally to mice injected with triple positive (EpCAM, CD133, CD44) sorted colon cancer stem cells in the xenograft cancer stem cell mice model. The complete regression of tumor was observed in 70% of mice fed on non-targeted (NT) NCs, with 30% mice showing tumor recurrence after 30 days, while only 10% mice fed with Tar NCs showed tumor recurrence indicating a significantly higher survival rate. From tumor tissue analyses of 35 apoptotic markers, 55 angiogenesis markers, 40 cytokines, 15 stem cell markers and gene expression studies of important signaling molecules, it was revealed that the anti-cancer mechanism of Fe3O4-bLf was intervened through TRAIL, Fas, Fas-associated protein with death domain (FADD) mediated phosphorylation of p53, to induce activation of second mitochondria-derived activator of caspases (SMAC)/DIABLO (inhibiting survivin) and mitochondrial depolarization leading to release of cytochrome C. Induction of apoptosis was observed by inhibition of the Akt pathway and activation of cytokines released from monocytes/macrophages and dendritic cells (interleukin (IL) 27, keratinocyte chemoattractant (KC)). On the other hand, the recurrence of tumor in AEC-CP-Fe3O4-bLf NCs fed mice mainly occurred due to activation of alternative pathways such as mitogen-activated protein kinases (MAPK)/extracellular signal-regulated kinases (ERK) and Wnt signaling leading to an increase in expression of survivin, survivin splice variant (survivin 2B) and other anti-apoptotic proteins Bad, Bcl-2 and XIAP. Apart from the promising anti-cancer efficacy and the exceptional tumor targeting ability observed by multimodal imaging using near-infrared (NIR) imaging, magnetic resonance imaging (MRI) and computerized tomographic (CT) techniques, these NCs also maintained the immunomodulatory benefits of bLf as they were able to increase the RBC, hemoglobin, iron calcium and zinc levels in mice.